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Mental Retardation (MR) is a developmental disability characterized by impairments in adaptive daily life skills and diﬃculties
in social and interpersonal functioning. Since multiple causes may contribute to MR, associated clinical pictures may vary
accordingly. Nevertheless, when psychiatric disorders as Treatment Resistant Depression (TRD) and/or alcohol abuse co-exist, their
proper detection and management is often troublesome, essentially due to a limited vocabulary MR people could use to describe
their symptoms, feelings and concerns, and the lack of reliable screening tools. Furthermore, MR people are among the most
medicated subjects, with (over) prescription of antidepressants and/or typical antipsychotics being the rule rather than exception.
Thus, treatment resistance or even worsening of depression, constitute frequent occurrences. This report describes the case of a
person with MR who failed to respond to repetitive trials of antidepressant monotherapies, finally recovering using aripiprazole
to fluvoxamine augmentation upon consideration of a putative bipolar diathesis for “agitated” TRD. Although further controlled
investigations are needed to assess a putative bipolar diathesis in some cases of MR associated to TRD, prudence is advised in the
long-term prescription of antidepressant monotherapies in such conditions.
1. Introduction
According to the American Association on Mental Retar-
dation (AAMR) [1] and the Diagnostic and Statistical
Manual of Mental Disorders Fourth Edition-Text Revision
(DSM-IV-TR) [2] definitions, mental retardation (MR)
is a developmental disability manifesting before age 18,
characterized by subaverage intelligence quotient (IQ <
70 according to DSM-IV-TR criteria) and impairments in
adaptive daily life skills [3]. In addition, a valid assessment
of cultural and linguistic diversity as well as diﬀerences in
communication, behavioral, and socioeconomic factors is
necessary to confirm the diagnosis [4].
Nonetheless, since diﬀerent criteria are adopted in
varying contexts worldwide, the prevalence of MR is
diﬃcult to estimate, also due to the broad underlying
etiology [5]. MR is estimated to aﬀect between 1% and
3% of the general population [6], but estimates vary
depending on sampling procedures, adopted definitions,
or even severity of intellectual disability [7]. Moreover,
especially for people with mild levels of MR, deficits are
not diagnosed until the school years, possibly delaying the
initiation of an appropriate multidisciplinary management
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[8]. Furthermore, prevalence data of MR tend to be generally
lower when the assessment method does not rely just on
intelligence but also on concurrent deficits in adaptive
behavior [9], which, conversely, could dramatically increase
in the presence of associated psychopathology [10], further
reducing the chance of a prompt accurate management
[11]. Specifically, the prevalence of comorbid psychiatric
and behavioral disorders is estimated to be three to four
times greater among people with MR than in the general
population [2]. The prevalence of psychopathology also
tends to increase with the severity of MR, suggesting that
people with more severe MR are at greater risk for mental
illness [12, 13]. There is also a high rate of pervasive develop-
mental disorders (e.g., autistic disorders, Rett’s disorder, and
childhood disintegrative disorder) among people with more
severe MR [14], while people with mild or moderate MR
and challenging behavior tend to exhibit behaviors related
to “cyclothymic-like” [15] hyperactivity [16], low frustration
tolerance [17], physical or verbal self- or hetero-directed
aggression, antisocial or socially inappropriate behavior [18],
alcohol abuse [19], and “agitated” depression [20], often
poorly responsive (“resistant”) to standard psychiatric drugs
[21]. Nonetheless, the use of psychotropic medications to
address psychopathology and behavior problems among
people with MR is well documented [22]. People with
MR receive many medical prescriptions, among the highest
in occidental populations [23, 24], and an estimated 30–
70% of individuals live in, or receive care by, institutional
facilities [24], thus accounting for a significant social cost
[25]. Nevertheless, the management of people with MR is
crucial [26] as the associated stigma [27] and suﬀerance
levels remain high [26], especially in light of the substantial
inappropriateness of standard screening instruments to
detect subthreshold symptoms (e.g., bipolar hints) in people
with MR [28].
In this report, we describe the case of a male subject with
MR who reported a history of alcohol abuse and Treatment
Resistant Depression (TRD) not adequately responding to
repetitive treatment with multiple antidepressant therapies.
Because of a hypothesized bipolar diathesis, the patient
finally responded to fluvoxamine and aripiprazole combina-
tion therapy, in the presence of a more adequate psychosocial
support.
2. Case
Mr. B.R., a 37-year-old Caucasian male diagnosed with
congenital mild MR (IQ = 65) measured using the Wechsler
Adult Intelligence Scale (WAIS) [29], followed from a welfare
medical institution since the age of 11, was first admitted
to a psychiatric facility at the age of 32, following life-
threatening alcohol abuse, without any apparent reason.
During his hospitalization, the patient was monitored both
for his medical diseases (Crohn’s disease diagnosed at age of
25 and congenital obstructive cardiomyopathy), which had
worsened in the previous months, and behavioral status. His
history, obtained with the assistance of relatives and friends,
revealed a previous, underrecognized, sporadic alcohol abuse
since the age of 30, which apparently began after mourning
for family reasons. Mood was low and the patient showed
contents of loss, incurability, and self-reproach (. . .I’m
responsible for the death of my father. . .) or (. . .I’m alone and
nobody likes me. . .), and (. . .”nobody could help me. . .”))
which lead to a diagnosis of major depressive episode (MDE)
according to the Structural and Clinical Interview for Axis-
I Disorders Patient’ edition (SCID-I/P) [30]. Remarkably,
according to the SCID-I/P criteria, an instrument not
validated for people with MR, B.R. had no lifetime personal
or familial history of hypomania or mania. Finally, a written
informed consent was obtained by the legal guardian of
the patient (his aunt), prior to receiving the prescription of
citalopram 40mg/day q.d., diazepam 10mg/day b.i.d., which
was confirmed two weeks later when he was discharged
from the hospital, with apparent resolution of depressive
and anxious symptoms. At discharge, we suggested to the
relatives of the patient and his social assistant to pay greater
attention to his habits and ensure the eﬀective adherence to
the therapy. Monthly observations at the outpatient facility
were also scheduled. Unexpectedly, after just 3 months
since discharge from the hospital, the patient repeated
alcohol abuse, with apparent representation of previous
depressive contents of thought, now accompanied by self-
injury behavior (hand biting) and hetero-directed anger.
In the following 3 years, the patient received a number
of diﬀerent “adequate” antidepressant trials, according to
the 2000 American Psychiatric Association (APA) guidelines
[31] developed for adults without intellectual disabilities,
including Selective Serotonin Reuptake Inhibitors (SSRIs)
other than citalopram (e.g., sertraline up to 200mg/day
and fluvoxamine up to 250mg/day), the Noradrenergic and
Specific Serotonergic Antidepressant (NaSSA) mirtazapine
(30mg/day) and the Serotonin Norepinephrine Reuptake
Inhibitor (SNRI) venlafaxine 225mg/day. Remarkably, none
of the above mentioned trials with antidepressant monother-
apies provoked substantial or long-lasting resolution of
alcohol abuse, behavioral abnormalities, or depression,
which led to the diagnosis of TRD according to DSM-IV-
TR criteria. Moreover, despite the nursing surveillance, the
patient performed a serious, life-threatening suicidal attempt
by ingestion of a large quantitative of an alcohol-based dis-
infectant two months after admission to a residential facility
following the death of his aunt, his legal guardian. Despite
not being validated for people with MR, the administration
of Hamilton Depression (HAM-D) and Anxiety (HAM-
A) rating scales assessed a considerable symptomatological
load, scoring 28 and 34, respectively. Finally, consider-
ing the repetitive treatment failure on antidepressant, the
worsening of behavioral status, the high suicidal risk even
under residential shelter and the hypothesis of a bipolar
diathesis for TRD, the patient was treated with fluvoxamine
200mg/day, augmented with the Atypical Antipsychotic
(AA) aripiprazole at 15mg/day. Since the use of aripiprazole
for nonpsychotic, unipolar depression still represents an
oﬀ-label prescription in our country, a written informed
consent was obtained by the new legal guardian (sister) upon
approval by local Ethical Committee. When reevaluated one
month after the new prescription, both the HAM-D and
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HAM-A appeared substantially reduced (to 6—a reduction
≥ 50% of the baseline score is considered remission-and 9,
respectively) [32] which, most importantly, lasted 6 months
after the initiation, favored by the assistance of a closer
psychosocial support.
3. Discussion
The use of AAs to treat TRD is not novel [33]. Nonetheless,
in many countries, AA prescription for patients without
prominent psychosis or full-threshold Bipolar Disorder
(BD), still represent an oﬀ-label prescription [34, 35]. This
is particularly true for special populations such as people
with MR, where the use of AAs remains a debated issue
[36]. In fact, MR has been reported to be associated with the
development of Extrapyramidal Syndromes (EPSs) even with
newer antipsychotics [36], which in turn may significantly
diﬀer from each other in terms of pharmacological and
tolerability profiles [37].
In our patient, the choice of aripiprazole augmentation
therapy was due to pharmacodynamics and pharmacokinet-
ics considerations. Aripiprazole, a second generation atypical
(third generation typical) antipsychotic, is characterized by
a unique pharmacodynamic profile combining partial D2
agonism, 5-HT2A blockade and partial 5-HT1A agonism
[38] and is metabolized by CYP2D6 and CYP3A4, thus pre-
venting any pharmacokinetic interaction with fluvoxamine
(CYP1A2). Also, the almost complete anticholinergic-free
profile of the two drugs permits their use even in course
of severe cardiologic conditions; conversely, Crohn’s disease
may benefit from a mild anticholinergic action (which could
contribute to reduced peristalsis). Fluvoxamine modulation
of the sigma-1 intracellular receptors may further contribute
to its eﬃcacy for MR-associated agitation as well as on
substance and alcohol abuse [39]. Additionally, the partial
5-HT1A agonism provided by aripiprazole (especially at the
anterior cingulate cortex) could potentially contribute to the
reduction in anxiety-related impulsive behavior (including
self-injuring and alcohol seeking). Finally, the D2-partial
agonism provided by medium-low doses (e.g., 15mg/day)
aripiprazole might improve anhedonia and other “negative”
depressive symptoms, preventing social withdrawal and
also contribute in reducing the risk of iatrogenic mixed
states or dysphoria potentially associated with antidepressant
monotherapy [40].
Moreover, while standard SSRIs (including fluvoxamine)
monotherapies have been reported to have a place in
the management of such conditions and related aggressive
behavior [41], concerns still remain about their eﬀective
long-term safety, especially when administered at higher
doses in the absence of mood stabilizers [42]. Chronic irri-
table dysphoria and irritability (“mixed states” or “agitated
depression”) [43, 44] may occur, although no controlled
trials have explored this outcome in samples of people with
MR. Additionally, while preliminary reports suggested a
potential role of lithium and other neuroprotective mood-
stabilizers for ethanol neurotoxicity [45, 46], their use for
people with intellectual disability is controversial [47] due to
methodological constraints of current evidences and the lack
of compliance these patients usually exhibit. Conversely, the
use of long-acting antipsychotic medication, which is part of
the routine clinical practice in people with MR diagnosed
with psychiatric disorders, should prompt concerns about
the chance of induction of tardive EPS and depression (again,
potentially occurring even with atypical antipsychotics) [48].
While a bipolar diathesis remains a major suspect in this
case, it is diﬃcult to definitely assess it due to the diﬃculty in
clinical history taking and limits of current rating scales [49].
Nonetheless, in the absence of a specific evidence base
for patients with MR in these regards, considering whether
the same approach and conceptual framework is eﬀective
for patients with MR and mental ill health is clearly
important. It is now generally recognized that people with
MR are overmedicated (with psychotropic medications) and
undertreated (i.e., inadequate assessment of symptoms and
behaviors of concerns, which while appearing “psychiatric”,
often have other etiologies such as physical illness (e.g.,
Crohn’s disease), or emotional responses (e.g., bereavement
and/or lack of adequate supports)) [50]. Therefore for
patients with MR presenting with “psychiatric” symptoms
and problem behaviors, any recommendations or sugges-
tions for treatment need to demonstrate robust diagnostic
assessment of these behaviors and symptoms of concern
including an assessment of their etiologies [51]. While this
is out of the scope (and possibilities) of a single case
report, even preliminary, noncontrolled observations may
contribute in shedding light on such a sensitive issue, ideally
prompting for more accurate replication surveys, yet it must
be remarked that at present time the hypothesis of a bipolar
diathesis for some cases of TRD in people with MR is just
speculative and robust replication studies are necessary to
investigate it further.
In people who do not have MR, subthreshold or tem-
peramental screenings, such as the Hypomania-Checklist-
32 items version (HCL-32) or the Temperament Evaluation
of the Memphis, Pisa, Paris, and San Diego Autoquestion-
naire (TEMPS-A), have been specifically developed to help
detecting bipolar depression overcoming actual DSM-IV-
TR categorical limits [52, 53] but to date no equivalent
screenings have been validated for people with MR, which
in turn remain very diﬃcult to assess also in consideration of
their wide clinical heterogeneity.
Regrettably, people with MR often receive inappropriate
management, which may be due not only to overmedication
(especially with psychotropic agents) [50], but also to disre-
gard of concomitant medical illness (e.g., Crohn’s disease—
which in this case might have contributed in the recurrence
of behavioral problems) [54, 55] and/or to inadequate
psychosocial support (remarkably, in this case the patient
exhibited a substantial recovery upon reconsideration of the
pharmacological therapy just when a better psychosocial
support was established). In fact, the demonstration of a
comprehensive biopsychosocial clinical understanding and
assessment of the patient with MR presenting with “psy-
chiatric” symptoms and problem behaviors and appropriate
nonmedication interventions being oﬀered, is now consid-
ered good practice before implementing amedication regime
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[50] so that it is hard to evaluate the impact of this specific
medication regime based just on a preliminary single case
report. Moreover, in the absence of such a comprehensive
and robust clinical review of the person with mental ill
health who has MR, there is the danger of perpetuating the
overmedication and the undertreatment that this population
has been exposed to over the years [50, 51].
Finally, considering the aforementioned limits of our
report, although the present case may suggest a potential
use of aripiprazole antidepressant augmentation for patients
with MR and alcohol abuse associated with TRD and
behavioral disturbances (agitated depression/mixed states),
the need for systematic, controlled studies, as well a better
appreciation of the complexity of the phenomenon and
of the respective role of diﬀerent supportive/therapeutic
approaches, is necessary to lead further insight about such
a sensitive issue.
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